Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Meta Expands AI Training With Employee Activity Tracking Tools 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
 Announces Annual Meeting of Stockholders - EconoTimes)
SHANGHAI, China and CUPERTINO, Calif., March 21, 2017 -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced that the Annual Meeting of Stockholders will be held on Friday, April 28, 2017. The meeting will be held at the Company’s office at 19925 Stevens Creek Blvd., Suite 100, Cupertino, California 95014 at 9:00 a.m. PDT. Stockholders of record as of March 10, 2017, the record date for the meeting, are authorized and asked to vote in the manner directed in the proxy materials.
A stockholder, once having received his/her proxy notice and access card, may view the proxy statement and related materials online or request a printed copy at www.iproxydirect.com/CBMG. Stockholders may vote online, by mail or by phone, according to the instructions on the proxy, no later than 11:59 p.m., Thursday, April 27, 2017, EDT. If your shares are held in the name of a bank, broker or other nominee, please check with your bank, broker or nominee and follow the voting instructions it provides. Please send an email to [email protected] if you have questions about the Annual Meeting or have not received your proxy notice card by post or by email.
About Cellular Biomedicine Group (CBMG)
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of cancer and degenerative diseases. We conduct immuno-oncology and stem cell clinical trials in China using products from our integrated GMP laboratory. Our GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. To learn more about CBMG, please visit www.cellbiomedgroup.com.
Contacts: Sarah Kelly Director of Corporate Communications, CBMG +1 408-973-7884 [email protected] Vivian Chen Managing Director Investor Relations, Citigate Dewe Rogerson +1 347 481-3711 [email protected]
